YAFO Capital is a Shanghai-based investment bank specialized in cross-border transactions with a focus on healthcare and biotech. We help clients identify the best strategic partners in China and advise in licensing and financing deals. Our key team are former research analysts and bankers in charge of China from Roth Capital and Evercore-ISI, with 25 on the ground team members performing due diligence and local communication in China for foreign clients. Over the last decade, we have built strong relationships with the top 100+ pharma and Medtech companies in China, which helped our global clients successfully license-out their products to the Chinese market. Our key business include: Investment Banking • Help overseas companies raise capital in China from strategic partners and financial investors • Licensing-in/out. Help companies find business partners in China (licensing and commercialization) • M&A Advisory Consulting & Valuation • Market research including clinical, regulatory, KOLs/Physician interviews, etc. in China • Product valuation: competitive landscape, sales forecast, valuation modeling, licensing structure proposal Investment • Investing directly through our own growth capital fund • Structured buy-out fund for mature stage companies